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Abstract
Minocycline, a tetracycline antibiotic, is known to exert vasculoprotective effects
independent of its anti-bacterial properties; however the underlying molecular mechanisms are
not completely understood. Reversion Inducing Cysteine Rich Protein with Kazal Motifs
(RECK) is a cell surface expressed, membrane anchored protein, and its overexpression inhibits
cancer cell migration. We hypothesized that minocycline inhibits platelet-derived growth factor
(PDGF)-induced human aortic smooth muscle cell (SMC) proliferation and migration via RECK
upregulation. Our data show that the BB homodimer of recombinant PDGF (PDGF-BB) induced
SMC migration and proliferation, effects significantly blunted by pre-treatment with minocycline.
Further investigations revealed that PDGF-BB induced PI3K-dependent AKT activation, MEKdependent ERK activation, reactive oxygen species generation, Nuclear Factor-κB and Activator
Protein-1 activation, microRNA (miR)-221 and miR-222 induction, RECK suppression, and
matrix metalloproteinase (MMP2 and 9) activation, effects that were reversed by minocycline.
Notably, minocycline induced RECK expression dose-dependently within the therapeutic dose of
1-100 μM, and silencing RECK partially reversed the inhibitory effects of minocycline on
PDGF-BB-induced MMP activation, and SMC proliferation and migration. Further, targeting
MMP2 and MMP9 blunted PDGF-BB-induced SMC migration. Together, these results
demonstrate that minocycline inhibits PDGF-BB-induced SMC proliferation and migration by
restoring RECK expression and inhibiting MMP activation. These results indicate that the
induction of RECK is one of the mechanisms by which minocycline exerts vasculoprotective
effects.
Keywords: Vascular Proliferative diseases, restenosis, mitogenesis, migration, PDGF,
RECK, MMP
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1. Introduction
Dysregulated proliferation and migration of arterial smooth muscle cells lead to vascular
complications, including intimal hyperplasia. Among various growth factors, the Plateletderived growth factor (PDGF) family exerts potent mitogenic and migratory effects on vascular
smooth muscle cells, ultimately resulting in intimal hyperplasia [1, 2]. There are four members in
PDGF family, PDGF-A, -B, -C and –D, that dimerize and signal via PDGF receptors alpha and
beta. Both PDGFRα and PDGFRβ are class III receptor tyrosine kinases, and form either homo
or heterodimers depending upon ligand binding [3]. Among various homo- or heterodimers of
members of the PDGF family, the PDGF-BB homodimer appears to be highly potent in exerting
mitogenic and migratory effects [3] via activation of multiple kinase-dependent signaling
cascades, including activation of PI3K/AKT and mitogen activated protein kinases [4, 5].
Furthermore, a significant role for oxidative stress and oxidative stress-sensitive NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells)-dependent signaling and its downstream
effectors microRNA (miR)-221 and miR-222 have also been implicated. However, the potential
targets of these miRs in the context of human arterial smooth muscle proliferation and migration
have yet to be fully identified.
Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) is a US Food and Drug
Administration (FDA)-approved second-generation, semi-synthetic, orally active tetracycline
antibiotic. However, its antibiotic-independent effects have also been described, including
vasculoprotection. In fact, minocycline has been shown to inhibit vascular endothelial growth
factor (VEGF)-induced aortic smooth muscle cell (SMC) migration by suppressing ERK
(Extracellular Signal-Regulated Kinase)- and PI3K (Phosphoinositide 3-Kinase)/AKT (V-Akt
Murine Thymoma Viral Oncogene Homolog)-dependent signaling and matrix metallopeptidase
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(MMP)-9 induction [6]. In fact, in a rat model of balloon injury, minocycline blunted neointima
formation by inhibiting MMP expression and SMC migration [6, 7]. Furthermore, minocycline
reduced atherosclerotic plaque size in apolipoprotein E-deficient mice, a murine model of
atherosclerosis, via a PARP1 (Poly[ADP-Ribose]Polymerase 1) and p27Kip1-dependent
suppression of SMC proliferation [8]. These reports suggest that minocycline may have
therapeutic potential in vascular proliferative diseases.
RECK (Reversion Inducing Cysteine Rich Protein with Kazal Motifs) is first described as
a tumor suppressor gene [9-12]. It is a glycosylphosphatidylinositol (GPI) anchored membrane
protein known to inhibit secretion and activation of MMPs. It is expressed in various cell types,
including adipocytes, vascular endothelial cells, smooth muscle cells, cardiomyocytes and
cardiac fibroblasts [13]. We have previously reported that ectopic expression of RECK
suppresses angiotensin II-mediated cardiac fibroblast migration in vitro and cardiac fibrosis in
vivo [14-16].
Many types of cancer cells express low levels of RECK, possibly contributing to their
malignant potential. Supporting this hypothesis, forced expression of RECK has been shown to
suppress cancer cell migration and proliferation [17, 18], suggesting that RECK inducers may
have therapeutic potential in lowering tumor growth, malignancy and metastasis. In an attempt to
identify small compounds that can induce Reck gene expression, Noda et al. have identified
minocycline as a potent activator of RECK promoter activity using a reporter gene assay in
RAS-transformed fibroblasts [19]. Here, we hypothesized that by upregulating RECK,
minocycline inhibits PDGF-induced human ASMC (SMC) proliferation and migration. Our
results show that PDGF-BB differentially regulates RECK and MMPs; suppresses RECK, but
induces MMPs activation; resulting ultimately in increased SMC proliferation and migration.
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Further supporting our hypothesis, minocycline reversed PDGF-BB-induced RECK suppression
and inhibited SMC proliferation and migration. To our knowledge, this is the first report
demonstrating the role of RECK in minocycline-induced suppression of PDGF-mediated SMC
proliferation and migration. Our data suggest a possible therapeutic role for minocycline and
other RECK inducers in vascular proliferative diseases.
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2. Materials and methods
2.1. Materials
Carrier-free recombinant human PDGF-BB protein was obtained from R&D Systems
(#220-BB; Minneapolis, MN). The gp91 ds-tat (YGRKKRRQRRRCSTRIRRQL - NH2; #AS63818) and its scrambled peptide control sgp91 ds-tat (YGRKKRRQRRRCLRITRQSR - NH2;
#AS-63821) were purchased from AnaSpec (Fremont, CA, USA). One of the major sources of
superoxide generation is NADPH oxidase (NOX). SMC express Nox2 (gp91phox) along with its
cell membrane and cytosolic components [20]. Binding of gp91phox to the p47-p67-p40phox
complex is critical in activation of Nox2. A specific gp91 docking sequence (ds in gp91 ds, blue)
which is responsible for binding of gp91phox and gp47phox is linked to a specific 9-amino acid
peptide of HIV (Human Immunodeficiency Virus) viral coat (HIV-tat, red), resulting in gp91 dstat which is used previously to block their interaction to disrupt Nox2 assembly and function. A
scrambled sequence linked to HIV-tat served as a control (sgp91 ds-tat) [20]. The Nox1/Nox4
inhibitor GKT137831 (2-2(chlorophenyl)-4-[3-(dimethylamino) phenyl]-5-methyl-1Hpyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; #17164) was purchased from Cayman Chemical
(Ann Arbor, MI). Minocycline (#9511), N-acetyl-L-cysteine (NAC; #A7250), cell culture
supplies, cOmplete™ Protease Inhibitor Cocktail (#11697498001), PhosSTOP™ (#4906845001),
Trypsin-EDTA solution (#T4049), Trypan Blue solution (#T8154), Dimethyl Sulfoxide (DMSO,
#D8418) and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). The
PI3K inhibitor Wortmannin (#S2758, 100 nM in DMSO for 1h), the AKT inhibitor MK-2206
2HCl (#S1078; a highly selective orally active pan-AKT inhibitor with no inhibitory activities
against 250 other protein kinases, 5µM for 1h), and the ERK inhibitor SCH772984 (#S7101; a
novel, specific inhibitor of ERK1/2, 10µM in DMSO for 1 h) were purchased from Sellechem
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(Houston, TX). RestoreTM Western blot Stripping Buffer (#21059), CyQUANT® Cell
Proliferation Assay (#C7026), Vybrant® MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) Cell Proliferation Assay Kit (#V13154), Amplex® Red Hydrogen
Peroxide/Peroxidase Assay Kit (#A22188), and Corning® BioCoat™ Matrigel® Migration
Chambers with 8.0μm polyethylene terephthalate (PET) membrane (#11563570) were purchased
from Thermo Fisher Scientific. Cell Death Detection ELISAPLUS kit (#11774425001) was
purchased from Roche Life Science (Indianapolis, IN). Human RECK (NM_021111; ~1.5 kb)
3’-UTR (untranslated region) clone in pMirTarget vector was purchased from Origene
(#SC214511, Rockville, MD). QuikChange II Site-Directed Mutagenesis Kit (#2000523) was
purchased from Agilent Technologies/Stratagene (Santa Clara, CA). Dual-Luciferase® Reporter
Assay System (#E1910) was purchased from Promega (Madison, WI). 96-well clear bottom,
black-sided plates (#29444-008) were purchased from VWR Scientific (West Chester, PA).
Polybrene® (sc-134220) was purchased from Santa Cruz Biotechnology, Inc. At the indicated
concentrations and for the duration of treatment, the pharmacological inhibitors failed to
modulate SMC morphology, viability or adherence to culture dishes (data not shown).

2.2. Cell culture-normal human aortic SMC
Normal human aortic smooth muscle cells (T/G HA-VSMC; SMC) were purchased from
ATCC (#CRL-1999, Manassas, VA, USA). The cells were authenticated by the vendor for
sterility (aerobic and anaerobic) and were pathogen-free. The cells were grown as previously
described [21] in Ham's F12 medium supplemented with 10% (vol/vol) FBS and endothelial cell
growth supplement (0.03 mg/ml). At 70–80% confluency, the complete medium was replaced
with Ham's F12/0.5% BSA. After 48 h, the quiescent SMC were incubated with PDGF-BB (10
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ng/ml) for the indicated time periods. At the end of the experimental period, cells were harvested,
snap frozen, and stored at −80°C. All other treatment conditions are detailed below and in figure
legends.

2.3. Adeno- and Lentiviral transduction
The following lentiviral shRNA vectors against IKKβ (#sc-35645-V), p65 (#sc-29410-V),
JNK2 (#sc-39101-V), and c-Jun (#sc-29223-V) were purchased from Santa Cruz Biotechnology,
Inc. Lentiviral shRNA against RECK (SHCLNV-NM_021111; TRCN0000376461) and eGFP
(SHC005V) were purchased from Sigma-Aldrich. All lentiviral vectors are previously described
[22, 23]. For lentiviral infection, SMC at 50–60% confluency were infected with the indicated
lentiviral shRNA at a multiplicity of infection (moi) of 0.5 for 48 h in complete media. To
increase infection efficiency, cells were co-treated with the cationic polymer Polybrene® (5
μg/ml in water). Neither shRNA nor Polybrene affected cell viability. The following adenoviral
vectors were used: RECK (Ad.RECK), MMP2 siRNA (Ad.siMMP2), MMP9 siRNA
(Ad.siMMP9), siGFP (Ad.siGFP), and eGFP (Ad.eGFP). All adenoviral vectors are previously
described [24, 25]. At ~70% confluency, CF were infected at ambient temperature with
adenoviruses in PBS at the indicated moi. After 1 h, the medium containing adenovirus was
replaced with fresh culture medium. Assays were carried out after 24h (RECK, eGFP) or 48h
(siMMP2, siMMP9, sieGFP). At the indicated moi and for the duration of treatment, adenoviral
vectors had no off-target effects, and failed to modulate SMC adherence, shape or viability
(trypan blue-dye exclusion; data not shown).
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2.4. miRNA expression, inhibitors and transfections
For miRNA expression, small RNA-enriched total RNA was isolated using
the mirVana™ miRNA Isolation Kit (Ambion®). Expression of human miR-221 (477981-mir)
and miR-222 (477982-mir) was analyzed using TaqMan® Advanced miRNA assays (Thermo
Fisher Scientific). U6 served as a loading control. Relative expression levels of microRNAs were
calculated using the 2-ΔΔCt method. Human miR-221 (has-miR-221, Assay ID: MH10337;
#4464084) -222 (Assay ID: MC11376; #4464066) inhibitors and an inhibitor control (AntimiR™ miRNA inhibitor negative control#1, #AM17010) were also purchased from Thermo
Fisher Scientific. SMC were transfected with the inhibitor or the inhibitor control (80 nM) as
previously described [16] using the Neon® transfection system (MPK-5000, Invitrogen) with the
following parameters: pulse voltage: 1300 volts, pulse width: 20 ms, pulse number: 2, and the tip
type: 10 μl, and then cultured for 24 h. SMC showed transfection efficiency of 51% with only
6% cell death as determined using the pEGFP-N1 vector. Transfections at the indicated
concentration and for the duration of treatment failed to significantly modulate SMC adherence,
shape or viability (trypan blue-dye exclusion; data not shown).

2.5. RECK 3’UTR analysis
Human RECK 3’UTR sequence was amplified and subcloned into pMIR-REPORT vector
(The Ambion® pMIR-REPORT™ miRNA Expression Reporter Vector System). Mutations in
miR-221/222 binding site (-AUGUAGC- to -UACAUCG-) [26] were introduced by site-directed
mutagenesis using the QuikChange II Site-Directed Muatagenesis Kit as previously reported [16]
and confirmed by nucleotide sequencing. SMC were transfected with the wild type (WT, RECK3’UTR) or mutant (mRECK-3’UTR) RECK pMIR-REPORTER vectors using the Neon®
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transfection system as described above with 3 µg of plasmid DNA for 24 h, co-transfected with
the Renilla luciferase vector (pRL-TK, 100 ng) prior to PDGF-BB addition (10 ng/ml for 12 h),
and analyzed for reporter activity using the Dual-Luciferase® Reporter Assay System, and the
results are presented as a ration of Firefly luciferase activity to that of corresponding Renilla
luciferase activity.

2.6. Superoxide and hydrogen peroxide production
Superoxide (O2−•) generation was quantified using the lucigenin-enhanced
chemiluminescence assay as previously described [24, 27]. After subtracting background
luminescence, results are expressed as pmol superoxide/min/mg protein. Studies were also
performed after treating cells with the Nox2 inhibitor gp91ds-tat (1 µM for 1 h). A
corresponding scrambled peptide served as a control. Hydrogen peroxide (H2O2) production was
measured according to the manufacturer’s instructions using a commercially available kit in the
presence of horseradish peroxidase (0.1 unit/ml, Amplex Red: and 50 µM) as has been
previously described [27]. Fluorescence was recorded at 530 nm excitation and 590 nm
emission wavelengths (CytoFluor II; Applied Biosystems, Foster City, CA). Standard curves
were generated using known concentrations of H2O2. Studies were also performed after
treatment with the Nox1/4 dual inhibitor GKT137831. The results are expressed as µM H2O2
produced/106 cells.

2.7. Immunoblotting and activity assays
Preparation of whole cell homogenates, immunoblotting, detection of the immunoreactive bands by enhanced chemiluminescence, and quantification by densitometry are all
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described previously [24, 27]. Immunoblotting was performed at least three separate occasions
(biological and not intra-assay variables), and a representative immunoblot is shown in the
figures. The source and concentration of antibodies used in immunoblotting are as follows:
AKT (#4685, 1:1000; Cell Signaling Technology, Inc/CST), phospho-AKT (Ser473; #4060,
1:1000, CST), ERK (#9102, 1:1000, CST), phospho-ERK (Thr202/Tyr204; #9101, 1:1000, CST),
Tubulin (#2144, 1:1000, CST), phospho-c-Jun (Ser63; #9261, 1:1000, CST), c-Jun (#9165,
1:1000, CST), IKKβ (#2370, 1:1000, CST), phospho-p65 (#3033, 1:1000, CST), p65 (#3034,
1:1000, CST), RECK (#3433, 1:1000, CST), cleaved caspase-3 (#9664, 1μg/ml, CST), JNK2
ab178953, 1:1000, abcam), caspase-3 (ab32499; 1:5000; abcam), MMP2 (detects both pro and
active forms; #AB19016, 1:2000, Millipore-Sigma), MMP2 (detects only the pro-form,
#MAB13405, 0.5 μg/ml, Millipore-Sigma), MMP9 (detects both pro and active forms;
#MAB3309, 1:2500, Chemicon, Temecula, CA), and MMP9 (detects only the pro-form;
MAB9111-SP; R&D Systems, Minneapolis, MN).

2.8. Transwell migration assays
SMC migration was quantified using the Discovery Labware BD BioCoat™ Matrigel™
invasion chambers (Cat. #354481, BD Biosciences) and 8.0-μm pore PET membranes with a thin
layer of Matrigel™ basement membrane matrix. Cultured SMCs were trypsinized and suspended
in Ham’s F12 medium and 0.5% BSA, and 1 ml containing 2.0 × 105 cells/ml was layered on the
coated insert filters. Cells were stimulated with PDGF-BB (10 ng/ml). The lower chamber
contained 20% FBS. After incubation at 37°C for 18 h, the membranes were removed and
washed with PBS, and the non-invading cells on the upper surface were removed with a cotton
swab. The cells migrating to the lower surface of the membrane were quantified using the MTT
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assay. In a subset of experiments, the layered cells were incubated with NAC, gp91 ds-tat,
GKT137831, minocycline, inhibitors of miR221, miR-222, lentiviral shRNA against RECK, or
respective controls prior to PDGF-BB addition.

2.9. Cell proliferation
The effects of PDGF-BB on SMC proliferation were analyzed according to
manufacturer's protocol using the CyQUANT® assay. Briefly, SMC were plated at 2x103 cells
per well into 96-well clear bottom, black-sided plates, and allowed to attach overnight. After
24 h, the cells were fed with serum-free medium containing 0.5% BSA and incubated for an
additional 24 h. Cells were then continuously stimulated with PDGF-BB (10 ng/ml) in serumfree medium for 48 h. After removing the medium, the plates were frozen at −80 °C for 2 h
before assay. Plates were then thawed, stained with CyQUANT® GR dye according to
manufacturer's protocol, and assayed on a FLX800 microplate fluorescence reader (Bio-Tek
Instruments, Winooski, VT) using 485/20 excitation and 528/20 emission filters, and analyzed
using KC4 software (Bio-Tek). Proliferation assays were carried out 6 times. To determine
the role of oxidative stress, miR-221, miR-222 and RECK, SMC were incubated with NAC,
gp91 ds-tat, GKT137831, minocycline, inhibitors of miR-221, miR-222, lentiviral shRNA
against RECK, adenoviral vectors expressing MMP2 and MMP9 silencing RNA, or respective
controls prior to PDGF-BB addition.

2.10. Cell death assays
To investigate whether minocycline induces cell death, SMC were cultured in complete
medium until ~70% confluent. The medium was replaced with Ham’s F12 medium with 0.5%
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BSA, and incubated for 48 h. Minocycline was added at the indicated doses, and analyzed for
cell death after 8 h by determining pro-caspase-3 (~35 kDa) and active-caspase-3 (~17/19 kDa)
levels by immunoblotting. As a positive control, H2O2 was added to a final concentration of 100
μM.

2.11. Statistical Analysis
Comparisons between controls and various treatments were performed by ANOVA with
post hoc Dunnett’s t-tests. All assays were performed at least three times, and the error bars in
the figures indicate the S.E. Though a representative immunoblot is shown in the main figures,
changes in protein/phosphorylation levels from three independent experiments were semiquantified by densitometry, and were shown as ratios and fold changes from untreated or
respective controls whenever the results are less clear.
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3. Results
3.1. Minocycline inhibits PDGF-BB-mediated PI3K/AKT- and ERK-dependent SMC
migration and proliferation without affecting cell viability.
Multiple signal transduction pathways are implicated in PDGF-induced SMC
proliferation and migration, including AKT and ERK activation. Therefore, we investigated
whether PDGF-BB induces SMC migration and proliferation via AKT and ERK activation, and
whether minocycline blunts these responses. Indeed, PDGF-BB induced time dependent AKT
activation, as evidenced by the increased levels of phosphor-AKT (Ser473) levels (Fig. 1A), an
effect inhibited by the PI3K inhibitor Wortmannin, the AKT inhibitor MK2206, and
mionocycline (Fig. 1B). Moreover, pre-treatment with Wortmannin, MK2206 and minocycline
each attenuated PDGF-BB-induced SMC migration (Fig. 1C) and proliferation (Fig. 1D) without
affecting cell viability (Fig. 1D, inset). However, hydrogen peroxide, used as a positive control,
induced cell death, as evidenced by increased levels of cleaved caspse-3 levels (Fig. 1D, inset).
Similarly, PDGF-BB induced time-dependent ERK activation, as evidenced by the increased
levels of phospho-ERK levels (Fig. 2A), an effect blunted by the ERK inhibitor SCH772984 and
minocycline. Further, inhibiting ERK activation attenuated PDGF-BB-induced SMC migration
(Fig. 2C) and proliferation (Fig. 2D), and without affecting cell viability (Fig. 2D, inset).
Hydrogen peroxide, used as a positive control, did induce cell death, as evidenced by increased
levels of cleaved caspse-3 levels (Fig. 2D, inset). Together, these results indicate that (i)
PDGHF-BB induces SMC migration and proliferation in part via AKT and ERK, and (ii)
pretreatment with minocycline inhibits AKT and ERK activation, and SMC migration and
proliferation, without affecting cell viability (Fig. 1 and Fig. 2).
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3.2. Minocycline inhibits PDGF-BB-induced reactive oxygen species generation and redoxsensitive SMC migration and proliferation
PDGF-BB has been shown to induce oxidative stress in various cell types. Since
minocycline exerts antioxidant effects, we next investigated whether PDGF-BB-mediated SMC
migration and proliferation is redox-sensitive manner, and whether minocycline blunts this
response. Indeed, PDGF-BB significantly increased superoxide generation, an effect markedly
attenuated by the broad- spectrum antioxidant NAC and the Nox2 inhibitor gp91 ds-tat (Fig. 3A).
PDGF-BB also stimulated hydrogen peroxide generation, an effect inhibited by NAC as well as
the Nox1/4 dual inhibitor GKT137831 (Fig. 3B). Furthermore, all three antioxidants, i.e., NAC,
gp91 ds-tat, and GKT137831, inhibited SMC migration and (Fig. 3C) and proliferation (Fig. 3D),
without affecting cell viability (Fig. 3E). Importantly, minocycline inhibited PDGF-BB-induced
superoxide and hydrogen peroxide (Fig. 3A, 3B). Together these results indicate that
minocycline blunts PDGF-BB-induced SMC migration and proliferation by inhibiting oxidative
stress (Fig. 3A).
The redox-sensitive nuclear transcription factors NF-κB and AP-1 (Activator Protein-1)
are essential mediators of PDGF signaling [28, 29]. Our data show that treatment with PDGF-BB
activated both transcription factors in a time-dependent manner, as evidenced by the increased
levels of phospho-p65 (Ser536) (Fig. 4A) and phospho-c-Jun (Ser63) (Fig. 4B). Since IKK and
JNK are upstream of NF-κB and AP-1, we next investigated whether silencing IKK and JNK
attenuate their activation. Indeed, while silencing IKKβ inhibited PDGF-BB-induced p65
phosphorylation (Fig. 4C), knockdown of JNK2 attenuated c-Jun phosphorylation (Fig. 4D).
Importantly, pretreatment with minocycline inhibited activation of both NF-κB and AP-1 (Fig.
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4C and 4D), consistent with its antioxidant effects and eventual inhibition of PDGF-BB-induced
NF-κB and AP-1 activation (Fig. 4).

3.3 PDGF-BB induces SMC migration and proliferation via IKK/NF-κB- and JNK/AP-1dependent miR-221 and miR-222 induction
Multiple microRNAs, including miR221 and miR-222, are shown to regulate PDGFinduced SMC migration and proliferation [30, 31]. Since both NF-κB and AP-1 regulate the
miR-221 and miR-222 induction, we next determined whether silencing targeting IKK/NF-κB
and JNK/AP-1 will inhibit their expression, and whether targeting miR-221 and miR-222 will
blunt PDGF-BB-induced SMC migration and proliferation. Results show that silencing IKKβ,
p65, JNK2 and c-Jun, each attenuated PDGF-BB-induced miR-221 (Fig. 5A) and miR-222 (Fig.
5D) expression. Further, the inhibitors of miR-221 and miR-222 each attenuated PDGF-BBinduced SMC migration (Fig. 5C) and proliferation (Fig. 5D), with affecting cell viability (Fig.
5E). Together, these data demonstrate that PDGF-BB induces SMC migration and proliferation
in part via IKK/NF-κB- and JNK/AP-1-dependent miR-221 and miR-222 induction (Fig. 5).

3.4. Targeting miR-221 and miR-222 reverses PDGF-BB-induced RECK suppression
We and others have previously demonstrated that the membrane-anchored MMP inhibitor
RECK is a potent inhibitor of cell migration [14, 15, 24, 26]. Therefore, we sought out to
determine the potential link between PDGF-BB, RECK, and miRs 221 and 222 in SMC. The
results show that SMC express RECK at basal conditions, and treatment with PDGF-BB
suppressed its expression (Fig. 6A). Further, targeting both miRs using respective inhibitors
reversed the inhibitory effects of PDGF-BB on RECK expression (Fig. 6A). Since miRs
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generally regulate gene expression by binding to the 3’ untranslated region (UTR) of target gene
mRNA, we next investigated whether miR-221 and miR-222 suppress RECK expression by
binding to its 3’-UTR. Our data show that while PDGF-BB suppressed RECK 3’-UTR
dependent reporter gene activation (Fig. 6B), mutating miR-221/222 binding site reversed its
inhibitory effects (Fig. 6B). These data indicate that miR-221 and miR-222 are essential
mediators of PDGF-BB-dependent signaling pathways downstream of NF-κB and AP-1 in
suppressing RECK expression (Fig. 6).

3.5. Minocycline inhibits SMC migration and proliferation via RECK induction
We have demonstrated that minocycline inhibits PDGF-BB-induced SMC migration and
proliferation (Fig. 1). Since PDGF-BB suppresses RECK expression (Fig. 6), and minocycline is
known to enhance RECK promoter activity [19], we next determined whether targeting RECK
reverses the inhibitory effects of minocycline on PDGF-BB-mediated SMC migration and
proliferation. Indeed, minocycline upregulated RECK expression in a dose-dependent manner up
to 50 μM (Fig. 7A), however, at a higher dose of 100 μM, RECK expression was lowered,
possibly due to reduced cell survival as evidenced by an increase in active (cleaved) caspase-3
levels (Fig. 7B). Further, minocycline (10 μM) upregulated RECK expression in a timedependent manner, reaching a plateau after 2 hours (Fig. 7C). To further confirm the role of
RECK in minocycline’s anti-migratory and anti-mitogenic effects, we targeted RECK expression
by a lentiviral shRNA (knockdown of RECK is shown as an inset in Fig. 7D, with TIMP3
serving as a off-target). Minocycline suppressed PDGF-BB-induced SMC migration by 80% (Fig.
5D) and proliferation by 50% (Fig. 5E), and these effects were reversed by RECK silencing (Fig.
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7D and 7E). These results indicate that RECK is an essential mediator of minocycline-mediated
inhibition of PDGF-BB-induced SMC migration and proliferation (Fig. 7).

3.6. RECK overexpression blunts PDGF-BB-induced SMC migration
MMPs play a critical role in extracellular matrix (ECM) degradation and agonist-induced
cell migration and proliferation [32]. Since PDGF-BB suppressed RECK (Fig. 6A), and as
RECK is a MMP regulator, including MMPs 2 and 9 [9, 17], we hypothesized that forced
expression of RECK will attenuate PDGF-BB-induced MMP activation and SMC migration and
proliferation. Indeed, PDGF-BB induced activation of both MMPs 2 and 9 (Fig. 8A), an effect
markedly inhibited by the pan-MMP inhibitor GM6001, corresponding specific inhibitors
(MMP2i and MMP9i), and most importantly, minocycline (Fig. 8A). Furthermore, forced
expression of RECK by adenoviral transduction inhibited PDGF-BB-induced MMP2 and MMP9
activation (Fig. 8B). Finally, silencing MMP2 and MMP9, each suppressed PDGF-BB-induced
SMC migration (Fig. 8C). Together, these data indicate that increased RECK suppresses PDGFBB-mediated SMC migration by inhibiting MMP activation (Fig. 8).
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4. Discussion
The molecular mechanisms underlying growth factor-induced smooth muscle cell
migration and proliferation have yet to be fully investigated. Here we report for the first time that
minocycline, a tetracycline antibiotic, inhibits PDGF-BB-mediated human aortic smooth muscle
cell (SMC) migration and proliferation by reversing RECK suppression. RECK is an MMP
inhibitor, and PDGF-BB suppressed its expression via AKT and ERK activation, ROS
generation, NF-κB and AP-1 activation, and miR-221 and miR-222 induction. Notably, RECK
overexpression blunted PDGF-BB-mediated MMP activation and SMC migration and
proliferation (Fig. 9). These results indicate that minocycline and other RECK inducers have the
potential to inhibit vascular proliferative diseases.
Our data show that minocycline inhibited multiple signal transduction pathways activated
by PDGF-BB, including AKT, ERK and oxidative stress. In fact, PDGF-BB signals via both
PDGFR α and β homo- or heterodimers, and that both receptor subunits have intrinsic tyrosine
kinase activity. It has been previously shown that binding of PDGF-BB to PDGFRβ results in
receptor tyrosine phosphorylation, and recruitment and activation of various second messengers,
including PI3K, resulting in AKT activation, ROS generation, and MAPK activation. PDGFBB/PDGFRβ signaling has also been shown to induce Ras-dependent ERK activation.
Activation of AKT, oxidative stress and ERK all have been shown to contribute to PDGF-BBmediated cell migration and proliferation. Importantly, our data show that by targeting all three
pathways, minocycline inhibited PDGF-BB-mediated SMC migration and proliferation.
Our results also show that minocycline inhibits PDGF-BB-induced superoxide and
hydrogen peroxide generation, confirming its antioxidant effects. Minocycline has been shown to
inhibit inducible nitric oxide synthase (iNOS) expression and iNOS-dependent nitric oxide
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generation. In fact, it has been shown to directly scavenge peroxynitrite, a product of reactive
oxygen and reactive nitrogen species. Lipid peroxidation resulting from increased oxidative
stress serves as a potential biomarker in vivo, and minocycline has been shown to inhibit lipid
peroxidation [33]. By inhibiting inflammatory mediators, minocycline has also been shown to
attenuate oxidative stress, suggesting that minocycline targeted multiple pro-oxidant mechanisms.
It has been demonstrated that its antioxidant effects stem from the phenol ring structure [34]. In
addition to radical scavenging, minocycline has also been shown to attenuate oxidative stress
indirectly by enhancing cellular antioxidant systems, such as increasing endogenous levels of
glutathione (GSH), and the induction of superoxide dismutase and glutathione peroxidase [35].
Of note, its free radical scavenging effects have been shown to be as effective as vitamin E [34].
In addition to inhibiting ROS generation, our data show that minocycline also inhibited
activation of the redox-sensitive transcription factors NF-κB- and AP-1, and miR-221 and miR222 induction. Moreover, inhibitors of these miRs attenuated PDGF-BB-induced SMC migration
and proliferation. The role of NF-κB and AP-1 in miR-221 and miR-222 expression has been
previously reported in prostate carcinoma and glioblastoma cells [36]. mir-221 and its paralogue
miR-222 are encoded in tandem on the X chromosome and are highly conserved throughout
vertebrate animals, including human, rat, and mouse. Their functions have been extensively
studied in tumorigenesis and metastasis [37-39]. They are also implicated in cardiovascular
diseases [40-42]. For example, in a rat model of injury-induced arterial stenosis, miR-221/222
are shown upregulated in SMCs in neointima and tunica media underneath the lesion [30], and
silencing miR-221/222 reduced neointimal thickening [30]. It has been previously reported that
PDGF-BB-induced miR-221 targets p27 (Kip1) and c-Kit in cultured vascular SMCs and
promotes cell cycle progression and de-differentiation [31]. Here, we found that both miRs -221
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and -222 directly target and downregulate RECK expression in SMC, facilitating PDGF-BBinduced proliferation and migration. Interestingly, in addition to targeting RECK, an MMP
inhibitor, both miRs have also been shown to target TIMP3 [43], another MMP inhibitor,
suggesting that increased expression of both miRs contribute to vascular proliferative diseases by
targeting MMP inhibitors. Though we have not investigated, it is highly likely that minocycline
might inhibit miR induction by targeting oxidative stress and induction of inflammatory
mediators.
Our data also show that minocycline inhibited PDGF-BB-mediated MMP activation. It
inhibited activation of both MMPs 2 and 9 in SMC. Multiple mechanisms might have
contributed to its inhibitory effects. For example, by targeting oxidative stress and activation of
redox-sensitive transcription factors like NF-κB and AP-1, minocycline might have inhibited
MMP2 and MMP9 activation. It is also possible that by suppressing the expression of
inflammatory mediators, which are known to increase MMP expression and activation. MMPs
are zinc-dependent endopeptidases, and minocycline has been shown to chelate Zn2+ [44]. Our
data show that minocycline upregulates the expression of RECK, an MMP inhibitor, indicating
that minocycline exerts multiple vasculoprotective effects
As discussed earlier, minocycline is a US FDA-approved broad-spectrum tetracycline
antibiotic. It has been on the market for more than 40 years and is prescribed as an oral or
systemic medication for treating acne vulgaris, skin infections, and sexually transmitted diseases.
Its short and relatively long term (~ 2 years) effects have also been tested as an-arthritic drug in
human subjects [45-49], with positive results. Such a history of safe use in human subjects even
in a relatively longterm application provides further support of minocycline’s therapeutic
potential in cardiovascular diseases. However, some limitations have been identified. Even
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though considered rare, minocycline administration has been shown to induce liver damage in
some subjects [50, 51]. Similarly, in a rat model of restenosis, minocycline administration
inhibited neointimal hyperplasia following arterial injury, but induced liver toxicity at the
therapeutic dose [7]. On the other hand, in a mouse model of atherosclerosis, minocycline
effectively prevented atherosclerosis and did not induce liver damage [8]. These reports suggest
that the range of the effective dose of minocycline may be narrow in human vascular
proliferative diseases, and thus should be carefully evaluated. Also in general, the long-term use
of antibiotics will result in antimicrobial resistance. Chemical engineering that mitigates the
antibacterial activity and toxicity may improve minocycline’s potential as an effective
therapeutic in vascular proliferative diseases. Alternatively, it would be useful to identify a
downstream effector of minocycline as a novel therapeutic agent, such as RECK induction. In
summary, our results suggest that the induction of RECK is one of the mechanisms by which
minocycline exerts vasculoprotective effects. Our results also suggest that RECK inducers may
have the potential to inhibit vascular proliferative diseases.
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Figure legends
Figure 1. Minocycline inhibits PDGF-BB-mediated AKT-dependent SMC
migration and proliferation. A, PDGF-BB induces time-dependent AKT activation. At 70-80%
confluency, SMC were made quiescent by incubating for 48 h in Ham's-F12/0.5% BSA, treated
with PDGF-BB (=10 ng/ml) for the indicated time period. AKT activation was analyzed in
cleared whole cell lysates using antibodies that detect activation-specific antibodies. Total AKT
served as a control (n=3). B, Minocycline inhibits PDGF-BB-induced PI3K-dependent AKT
activation. Quiescent SMC were incubated with the PI3K inhibitor Wortmannin (100 nM in
DMSO for 1h), the AKT inhibitor MK2206 (5µM for 1h), or minocycline (10 μM for 15 min)
prior to PDGF-BB addition (10 ng/ml for 30 min). AKT activation was analyzed as in A (n=3).
C, Minocycline inhibits PI3K/AKT-dependent SMC migration. Quiescent SMC were layered on
Matrigel™ basement membrane matrix-coated filters, incubated with Wortmannin, MK2206 or
minocycline as in B prior to PDGF-BB (10 ng/ml) addition. The lower chamber contained 20%
FBS. After 18h, cells migrated to the lower side of the membrane were quantified using MTT
assay (n=6). D, Minocycline inhibits PI3K/AKT-dependent SMC proliferation without
modulating cell viability. Quiescent SMC incubated as in B were analyzed for proliferation after
48h by CyQUANT® Cell Proliferation Assay (n=8). Activation of caspase-3, as an indication of
reduced cell viability, was analyzed by immnoblotting (inset, n=3). Hydrogen peroxide (H2O2,
100 μM) served as a positive control. A, B, Immunoreactive bands from three independent
experiments were semiquantified by densotometry, and summarized in the respective lower
panels. *P< 0.01 vs. untreated, †P< at least 0.05 vs. PDGF-BB (n=6).
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Figure 2. Minocycline inhibits PDGF-BB-mediated ERK-dependent SMC
migration and proliferation. A, PDGF-BB induces time-dependent ERK activation. At 70-80%
confluency, SMC were made quiescent by incubating for 48 h in Ham's-F12/0.5% BSA, treated
with PDGF-BB (=10 ng/ml) for the indicated time period. ERK activation was analyzed in
cleared whole cell lysates using antibodies that detect activation-specific antibodies. Total ERK
served as a control (n=3). B, Minocycline inhibits PDGF-BB-induced ERK activation. Quiescent
SMC were incubated with the ERK inhibitor SCH772984 (10µM in DMSO for 1 h) or
minocycline (10 μM for 15 min) prior to PDGF-BB addition (10 ng/ml for 30 min). ERK
activation was analyzed as in A (n=3). C, Minocycline inhibits ERK-dependent SMC migration.
Quiescent SMC were layered on Matrigel™ basement membrane matrix-coated filters, incubated
with SCH772984 or minocycline as in B prior to PDGF-BB (10 ng/ml) addition. The lower
chamber contained 20% FBS. After 18h, cells migrated to the lower side of the membrane were
quantified using MTT assay (n=6). D, Minocycline inhibits ERK-dependent SMC proliferation
without modulating cell viability. Quiescent SMC incubated as in B were analyzed for
proliferation after 48h by CyQUANT® Cell Proliferation Assay (n=8). Activation of caspase-3,
as an indication of reduced cell viability, was analyzed by immnoblotting (inset, n=3). Hydrogen
peroxide (H2O2, 100 μM) served as a positive control. A, B, Immunoreactive bands from three
independent experiments were semiquantified by densotometry, and summarized in the
respective lower panels. *P< 0.01 vs. untreated, †P< at least 0.05 vs. PDGF-BB (n=6).

Figure 3. Minocycline inhibits PDGF-BB-induced oxidative stress and oxidative
stress-responsive SMC migration and proliferation. A, B, Minocycline inhibits PDGF-BBinduced superoxide and hydrogen peroxide (H2O2) generation. Quiescent SMC were incubated
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with PDGF-BB for 15 (A) or 30 (B) min. Superoxide anion (O2-•; A) and H2O2 (B) production
were analyzed by cytochrome C assay and Amplex red assay, respectively (n=6). In a subset of
experiments, quiescent SMC were incubated with NAC (5mM in water for 30 min), a peptide
inhibitor of Nox2 (gp91 ds-tat; 1 µM for 1 h), the Nox1/4 inhibitor GKT137831 (5 μM in DMSO
for 15 min) or minocycline (10 μM for 15 min) prior to PDGF-BB addition. Scrambled gp91 dstat (sgp91 ds-tat) and DMSO served as controls. C, Minocycline inhibits PDGF-BB-induced
oxidative stress-responsive SMC migration. Quiescent SMC were layered on
Matrigel™ basement membrane matrix-coated filters, incubated with PDGF-BB (10 ng/ml) for
18 h. The lower chamber contained 20% FBS. Cells migrated to the lower side of the membrane
were quantified using MTT assay. In a subset of experiments, SMC were treated with NAC,
gp91 ds-tat, GKT137831, or minocycline as A and B prior to PDGF-BB addition. D, E,
Minocycline inhibits PDGF-BB-induced SMC proliferation (D) without affecting cell viability
(E). Quiescent SMC incubated as in A and B were analyzed for proliferation after 48h by
CyQUANT® Cell Proliferation Assay. Activation of caspase-3, as an indication of reduced cell
viability, was analyzed by immnoblotting (E, n=3). Hydrogen peroxide (H2O2, 100 μM) served
as a positive control. *P< 0.01 vs. untreated, †P< 0.01 vs. PDGF-BB (n=6).

Figure 4. Minocycline inhibits PDGF-BB-induced NF-κB and AP-1 activation. A,
PDGF-BB induces time-dependent NF-κB activation. Quiescent SMC were incubated with
PDGF-BB (10 ng/ml). At the indicated time periods, activation of NF-κB was analyzed by
immunoblotting using antibodies that specifically detect phosphorylated p65 at Ser536. B, PDGFBB induces time-dependent AP-1 activation. Quiescent SMC incubated as in A were analyzed
for AP-1 activation by immunoblotting using antibodies that specifically detect phosphorylated
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c-Jun at Ser73. C, Silencing IKKβ or pre-treatment with minocycline inhibit PDGF-BB-induced
NF-κB activation. SMC incubated with lentiviral IKKβ shRNA (moi0.5 for 48 h) were made
quiescent and treated with PDGF-BB (10 ng/ml for 30 min). In a subset of experiments,
quiescent SMC were incubated with minocycline (10 μM for 15 min) and then treated with
PDGF-BB (10 ng/ml for 30 min). Activation of NF-κB was analyzed as in A. D, Silencing JNK2
or pre-treatment with minocycline inhibits PDGF-BB-induced AP-1 activation. SMC incubated
with lentiviral JNK2 shRNA (moi 0.5 for 48 h) were made quiescent and treated with PDGF-BB
(10 ng/ml for 30 min). In a subset of experiments, quiescent SMC were incubated with
minocycline (10 mM for 15 min) and then treated with PDGF-BB (10 ng/ml for 30 min).
Activation of AP-1 was analyzed as in B. Silencing IKKβ and JNK2 was confirmed by
immunoblotting. JNK2 and IKKβ served as off-targets in IKKβ and JNK2 silenced cells,
respectively (right hand panels in C and D). Tubulin served as a loading control. Bar graphs at
the bottom of panels in A-D represent densitometric analyses from three independent
experiments. *P<0.05 control, †P<0.05 versus PDGF-BB (n=3).

Figure 5. PDGF-BB induces SMC proliferation in part via miR-221 and miR-222. A,
B, PDGF-BB induces miR-221 (A) and miR-222 (B) expression via IKKβ, NF-κB, JNK and AP1. Quiescent SMC incubated with PDGF-BB (10 ng/ml) for 1h were analyzed for miR-221 (A)
and miR-222 (B) expression by TaqMan® Advanced miRNA assays. The results were
normalized to corresponding U6 expression. In a subset of experiments, SMC were incubated
with lentiviral IKKβ, p65, JNK2 or c-Jun shRNA (moi0.5 for 48 h), made quiescent and then
treated with PDGF-BB addition. C, D, miR-221 and miR-222 mediate PDGF-induced SMC
migration (C) and proliferation (D), without affecting cell viability (E). SMC were transduced
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with miR-221 or miR-222 inhibitors prior to the addition of PDGF-BB (10 ng/ml). Cell
migration was analyzed after 18 h using transwell migration assays (C). Cell proliferation was
analyzed after 48h by CyQUANT® Cell Proliferation Assay (D). Cleaved caspase-3 levels,
indicative of cells undergoing apoptosis, was analyzed after 8 h by immunoblotting using
antibodies that detect both total and cleaved caspase-3 levels (E). Hydrogen peroxide (H2O2, 100
μM) served as a positive control. *P<at least 0.05 versus control, †P<0.05 versus PDGF-BB
(n=6).

Figure 6. PDGF suppresses RECK expression via miR-221 and miR-222. A,
Inhibitors of miR-221 and miR-222 reverse PDGF-BB-induced RECK suppression. Quiescent
SMC were transfected with miR-221 or miR-222 inhibitor or the negative control (80 nM) using
the Neon® transfection system. Twenty four-hours later, cells were treated with PDGF-BB (10
ng/ml for 24 h), and then analyzed for RECK protein levels by immunoblotting (n=3). B,
Mutating miR-221/miR-222 binding site in RECK 3’UTR reverses PDGF-BB-induced RECK
suppression. SMC transfected with wild type (WT) or miR-221/222 mutant (mutant) RECK
3’UTR reporter vector (3 µg) along with pRL-Tk vector (100 ng) for 24 h were treated with
PDGF-BB (10 ng/ml for 12 h), and then harvested for dual luciferase activity (n=6). *P < at least
0.05 versus untreated, †P < at least 0.05 versus PDGF-BB (A) or WT (B) mutant RECK 3’UTR
(n=3-6).

Figure 7. Minocycline inhibits PDGF-BB-induced SMC migration and proliferation
in part by upregulating RECK expression. A, Minocycline induces RECK expression in a
dose-dependent manner. Quiescent SMC were treated with minocycline at indicated
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concentrations for 2h, and analyzed for RECK induction by immunoblotting (n=3). B,
Minocycline induces SMC death only at a higher concentration. Quiescent SMC were treated
with minocycline at the indicated doses for 12 h, and analyzed for total and cleaved caspase-3
levels by immunoblotting (n=3). C, Minocycline induces RECK expression in a time-dependent
manner. Quiescent SMC incubated with minocycline (10 μM) for the indicated time periods
were analyzed for RECK expression by immunoblotting as in A (n=3). D, Silencing RECK
reverses the inhibitory effects of minocycline on PDGF-BB-induced SMC migration. Quiescent
SMC layered on Matrigel™ basement membrane matrix-coated filters were treated with
minocycline (10 μM for 15 min) prior to the addition of PDGF-BB (10 ng/ml for 18 h). The
lower chamber contained 20% FBS. Cells migrated to the lower side of the membrane were
quantified using MTT assay (n=6). E, Silencing RECK reverses the inhibitory effects of
minocycline on PDGF-BB-induced SMC proliferation. Quiescent SMC incubated as in D, but
for 48 h, and analyzed for proliferation by CyQUANT® Cell Proliferation Assay (n=6). *P<at
least 0.05 versus control, †P<0.05 versus PDGF-BB, §P<0.05 versus PDGF-BB+minocycline
(n=3-6).

Figure 8. Minocycline and forced expression of RECK inhibit PDGF-BB-induced
MMP-2 and MMP-9 activation. A, Minocycline inhibits PDGF-BB-induced MMP2 (left panel)
and MMP9 (right panel) activation. Quiescent SMC were incubated with minocycline (10 μM
for 2 h) prior to PDGF-BB addition (10 ng/ml for 2 h). Activation of MMP2 and MMP9 were
analyzed by immunoblotting using antibodies that detect both pro and active forms (n=3). In a
subset of experiments, quiescent SMC were incubated with inhibitors of MMP2 (MMP2i-II; 2.5
mM in DMSO for 1 h), MMP9i (100 nM in DMSO for 1 h), or pan-specific MMP inhibitor
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GM6001 (10 μM in DMSO for 15 min) prior to PDGF-BB addition. B, Forced expression of
RECK inhibits MMP2 and MMP9 activation. SMC were transduced with adenoviral RECK (moi
10 for 24 h) prior to PDGF-BB addition (10 ng/ml for 2 h). Activation of MMP2 (left panel) and
MMP9 (right panel) were analyzed as in A (n=3). C, Silencing MMP2 or MMP9 attenuates
PDGF-BB-induced SMC migration. SMC transduced with adenoviral MMP2 or MMP9 siRNA
(moi100 for 48 h) were treated with PDGF-BB (10 ng/ml for 18 h) and then analyzed for
migration (n=6). Knockdown of MMP2 and MMP9 was analyzed by immunoblotting as shown
on the right. MMP9 and MMP2 served as off-targets in MMP2 and MMP9 silenced cells,
respectively. *P<at least 0.05 versus control, †P<0.05 versus PDGF-BB (n=3-6).

Figure 9. Schema showing the possible signal transduction pathways targeted by
minocycline in reversing PDGF-BB-mediated RECK suppression and human aortic
smooth muscle cell proliferation and migration. While PDGF-BB induced AKT and ERK
activation, oxidative stress, NF-κB and AP-1 activation, miR-221 and miR-222 induction, MMP
activation, and RECK suppression, resulting ultimately in SMC proliferation and migration.
Pretreatment with minocycline reversed these effects (blue arrowheads). Moreover, minocycline
induced RECK expression (red diamond) and silencing RECK reversed the inhibitory effects of
minocycline on PDGF-BB-induced MMP activation and SMC migration and proliferation. These
results suggest a therapeutic potential for minocycline in vascular proliferative diseases. Broken
arrows: Published reports.
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